The symposium and publication of this video was funded by Helsinn.
Prescribing Information for LEDAGA®️ (chlormethine hydrochloride) can be found here. Local prescribing conditions may vary. Please refer to prescribing information in your country of practice. Always consult local prescribing information in country of practice as information may vary. Adverse Events Reporting information can be found at the bottom of this webpage.
This symposium was presented at the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumour Group Annual Meeting, held between 16th–18th October, 2025 in Athens, Greece, with a focus on:
- The Evolving Lens: Rethinking MF-CTCL Through Clinical and TME Insights
- Linking Tumour Immune Infiltration to Dermatitis and Clinical Outcomes in Mycosis Fungoides Patients Treated with Chlormethine Gel
- Exploring the Potential of CL Gel’s Effect: CD8+ T Cell Populations in Responders vs. Non Responders – Changes in Tumour Microenvironment During Treatment in Cutaneous T-cell Lymphoma
Speakers:
Evangelia Papadavid1,2
Maarten Vermeer1,3
1. EORTC Cutaneous Lymphoma Tumour Group, Brussels, Belgium
2. National and Kapodistrian University of Athens, Greece
3. Leiden University Medical Center, the Netherlands
Adverse events should be reported. Reporting forms and information for the United Kingdom can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Helsinn Healthcare SA via email at [email protected].
